The intended audience for this annual, one-day educational program included students, postdoctoral fellows and technicians from academia and industry, as well as physicians and scientists at more senior levels who wish to solidify their understanding of tumor immunology and immunotherapy.
Upon completion of this meeting, participants are able to:
- Describe the key principles of tumor immunology and immunotherapy
- Summarize the basic principles of passive immunotherapy, in which antibodies or T lymphocytes generated outside of the patient are administered with therapeutic intent
- Discuss the techniques involved in active immunotherapy, including tumor antigen vaccination as well as immune checkpoint blockade
- Outline immune monitoring techniques, both in peripheral blood and sera, as well as in patient samples collected in pre-surgical trials
- Enhance scientific exchange with colleagues and collaborators on research and application of cancer immunotherapies to improve outcomes of patients with cancer
Click here for information on continuing medical education credits available through the Primer on Tumor Immunology and Cancer Immunotherapy™.
The SITC Primer on Tumor Immunology and Cancer Immunotherapy™ was supported in part by a grant from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Incyte Corporation and Merck & Co., Inc.